Sanford Burnham Prebys

File:Burnham logo.jpg

Sanford Burnham Prebys originated in 1976 as the La Jolla Cancer Research Foundation, founded by Dr. William H. Fishman and Lillian Waterman Fishman after he retired from Tufts University School of Medicine.{{Cite web |title=Our History |url=https://sbpdiscovery.org/about/our-history/ |access-date=2025-05-24 |website=Sanford Burnham Prebys |language=en-US}}

The institute was renamed the Burnham Institute in 1996 after a $10 million contribution from philanthropist Malin Burnham and an anonymous donor. In 2006, the name was changed to the Burnham Institute for Medical Research.

In 2007, T. Denny Sanford pledged $20 million through Sanford Health, supporting the creation of the Sanford Children's Health Research Center in La Jolla, California, and Sioux Falls, South Dakota.{{Cite web |last=Staff |first=S. H. N. |date=2007-11-18 |title=Denny Sanford donates $20 million for pediatric research |url=https://news.sanfordhealth.org/news/philanthropist-denny-sanford-donates-20-million-for-pediatric-research/ |access-date=2025-05-24 |website=Sanford Health News |language=en}}

A $97.9 million grant from the National Institutes of Health in 2008 supported the development of a small-molecule screening center.{{cite web |last=Savage |first=Sam |date=2008-09-02 |title=Burnham Awarded $97.9 Million NIH Grant to Expand Small-Molecule Screening and Discovery Center |url=http://www.redorbit.com/news/science/1540494/burnham_awarded_979_million_nih_grant_to_expand_smallmolecule_screening/ |access-date=2025-05-06 |website=Red Orbit}}

Following a $50 million gift from Sanford in 2010, the institute was renamed Sanford-Burnham Medical Research Institute.{{Cite web |date=2010-01-25 |title=BIOMED: It’s now Sanford-Burnham after $50M donation to research institute |url=https://www.sandiegouniontribune.com/2010/01/25/biomed-its-now-sanford-burnham-after-50m-donation-to-research-institute/ |access-date=2025-05-06 |website=San Diego Union-Tribune |language=en-US}} In 2014, a $275 million pledge was announced but was later reduced to $200 million.{{cite news |last=Robbins |first=Gary |date=2018-03-13 |title=Donor cuts $75 million from gift to Sanford Burnham Prebys |url=https://www.sandiegouniontribune.com/news/science/sd-me-sanfordburnham-donation-20180313-story.html |access-date=2025-05-06 |newspaper=San Diego Union-Tribune}}

In 2015, a $100 million gift from Conrad Prebys resulted in the institute's current name: Sanford Burnham Prebys.{{Cite news |date=2016-06-24 |title=Conrad Prebys Donates $100 Million to Sanford-Burnham |url=https://finance.yahoo.com/news/conrad-prebys-donates-100-million-180000671.html |access-date=2025-05-06 |work=Marketwired}}{{Cite web |last=Harvey |first=Kate |title=What's in a Name? |url=https://www.philanthropyroundtable.org/magazine/spring-2017-whats-in-a-name/ |access-date=2025-05-06 |website=Philanthropy Roundtable |language=en-US}}

Dr. David Brenner became President and CEO in 2022.{{Cite web |last=Freeman |first=Mike |date=2022-09-09 |title=Sanford Burnham Prebys gets new CEO from UC San Diego |url=https://www.sandiegouniontribune.com/2022/09/09/sanford-burnham-prebys-gets-new-ceo-from-uc-san-diego/ |access-date=2025-05-06 |website=San Diego Union-Tribune |language=en-US}}

{{Promotional|date=March 2025|section}}

Sanford Burnham Prebys was founded with its primary focus on cancer research. As of June 2024, Sanford Burnham Prebys employed 45 Principal Investigators and a total of 500 staff members.{{Cite web |last=Williams |first=Geshawn |date=2025-01-23 |title=Fitch Affirms Sanford Burnham Prebys Medical Discovery Institute, CA at 'A'; Outlook Stable |url=https://www.fitchratings.com/research/us-public-finance/fitch-affirms-sanford-burnham-prebys-medical-discovery-institute-ca-at-a-outlook-stable-23-01-2025 |access-date=2025-05-06 |website=Fitch Ratings}} The staff consists of postdoctoral researchers, graduate students, and administrative and support personnel.

The institute is home to six research centers:

• NCI-designated cancer center
• Infectious and Inflammatory Disease Center
• Center for genetic disorders and aging research
• Sanford Children's Health Research Center
• Conrad Prebys Center for chemical genomics
• Center for Stem Cells and regenerative medicine

It also partners with the San Diego Nathan Shock Center for Aging Research alongside the Salk Institute and UC San Diego.

There are seven research programs at Sanford Burnham Prebys:

The program aims to improve understanding how cells discriminate between functional and nonfunctional proteins. It further researches the damaging impact of oxidative stress on protein structure and function in the neurodegenerative diseases of Alzheimer's and Parkinson's, metabolic diseases of diabetes and liver failure, and inflammatory disease and cancer. The aim is to develop new therapies that improve protein folding and preserve cell function in diseases that have a global health impact.

The program includes research on:

• gene functions linked to mutations and epigenetic factors {{Citation needed|date=March 2025}}.

• the development and regenerative capacity of the brain, heart, muscles, pancreas, limbs, liver, and other organs;{{Citation needed|date=March 2025}}
• the biology of aging and organ/tissue maintenance to maintain a well-functioning organism with the aim to find novel therapeutic targets for cardiovascular disease, neurodegeneration, muscle disorders, diabetes, cancer, and other diseases.{{Citation needed|date=March 2025}}

Research is mainly conducted using common model organisms such as mice, fish, flies, worms, as well as human stem cells.

The program's primary focus is on improving the understanding of known and newly discovered genetic disorders using common model organism such as zebrafish, mouse models, patient cell cultures, and stem cells. This research has led to diagnostic tests and novel therapies for patients.

The program's primary focus is to understand the regulation and interplay of host immune responses and microbial pathogenesis; viral-host interactions, innate and humoral immunity, inflammation, and T cell checkpoint regulation. The aim is to develop new therapies addressing endemic and pandemic infectious diseases, autoimmune disorders, cancer, and inflammatory diseases.

The focus of this program is on RNA biology and the signaling pathways that regulate cell growth and cell fate; research of cancer cells' growth factors, development of treatment methods for brain, breast, and prostate cancers, melanoma, and leukemia.

{{unreferenced section|date=October 2024}}

In addition to its research mission, Sanford Burnham Prebys provides education. Established in 2005, the institute's Graduate School of Biomedical Sciences offers a Ph.D. degree in Biomedical Sciences.{{Cite web |title=Graduate School of Biomedical Sciences |url=https://sbpdiscovery.org/education/graduate-school/ |access-date=2025-05-22 |website=Sanford Burnham Prebys |language=en-US}} In 2015, Sanford Burnham Prebys achieved accreditation with the Western Association of Schools and Colleges. Sanford Burnham Prebys also trains and employs postdoctoral fellows;{{Cite web |title=Postdoctoral Training |url=https://sbpdiscovery.org/education/postdoctoral-training/ |access-date=2025-05-22 |website=Sanford Burnham Prebys |language=en-US}} with typically 125 postdocs training at the Institute at any time.

The graduate school is focused on biomedical research and is supplemented by the technologies developed to facilitate the development of medical practices. The program offers a foundation in biomedical science and projects in biology, chemistry, bioinformatics, and engineering, with a focus on one of the main foundations of biomedical science within a laboratory specializing in the area.

The program provides eight openings per year with a total number of thirty students. Entering graduate students are admitted to their thesis labs on day one and do not perform laboratory rotations. In the first two years, students complete five core courses, six tutorials, and one elective. Instructions are accompanied by practical laboratory training under the supervision of faculty.

{{unreferenced section|date=October 2024}}

In January 2020, Sanford Burnham Prebys reported $117M in annual revenue.{{Citation needed|date=July 2025}}

The sources of funding in 2019 were: 58% federal, 22% private philanthropy, 8% biopharmaceutical partnerships, 8% licensing and other, and 4% other grants.{{Citation needed|date=July 2025}}

Donations from the Whittaker Corporation and the California Foundation enabled the acquisition of a five-acre site on the La Jolla mesa. The philanthropists' donations, alongside the institute's namesakes, including T. Denny Sanford, Malin and Roberta Burnham, and Conrad Prebys, have helped ensure the institute's continued growth.{{Citation needed|date=July 2025}}

The Institute initially focused on the commonalities between cancer and fetal development, known as onco-developmental biology. Significant early discoveries include the development of monoclonal antibody-based 'two-site' ELISA. In the 1980s, the Institute was recognized for its work on fibronectin and other extracellular matrix components, including cell adhesion. This work includes the discovery of the RGD tripeptide as the cell attachment site in fibronectin, fibrinogen, and other adhesive proteins, alongside the discovery of integrins, the cell surface receptors that recognize the RGD sequence in matrix proteins.{{cite journal |last1=Ruoslahti |first1=Erkki |last2=Pierschbacher |first2=Michael D. |title=New Perspectives in Cell Adhesion: RGD and Integrins |journal=Science |date=23 October 1987 |volume=238 |issue=4826 |pages=491–497 |doi=10.1126/science.2821619 |pmid=2821619 |bibcode=1987Sci...238..491R }}

In the 1990s, Institute scientists achieved prominence by contributing to research on programmed cell death, discovering several previously unknown pro- and anti-apoptotic proteins, namely caspases, IAPs, and Bcl-2 family members.{{cite journal |last1=Salvesen |first1=Guy S |last2=Dixit |first2=Vishva M |title=Caspases: Intracellular Signaling by Proteolysis |journal=Cell |date=November 1997 |volume=91 |issue=4 |pages=443–446 |doi=10.1016/S0092-8674(00)80430-4 |pmid=9390553 |s2cid=5377068 |doi-access=free }}{{cite journal |last1=Deveraux |first1=Quinn L. |last2=Takahashi |first2=Ryosuke |last3=Salvesen |first3=Guy S. |last4=Reed |first4=John C. |title=X-linked IAP is a direct inhibitor of cell-death proteases |journal=Nature |date=July 1997 |volume=388 |issue=6639 |pages=300–304 |doi=10.1038/40901 |pmid=9230442 |s2cid=4395885 |doi-access=free |bibcode=1997Natur.388..300D }}{{cite journal |last1=Reed |first1=John C. |title=Bcl-2–family proteins and hematologic malignancies: history and future prospects |journal=Blood |date=April 2008 |volume=111 |issue=7 |pages=3322–3330 |doi=10.1182/blood-2007-09-078162 |pmid=18362212 |pmc=2275002 }}

The demonstration by Institute scientists that cells deprived of attachment to extracellular matrix commit suicide by apoptosis, named Anoikis, connected the fields of cell adhesion and apoptosis.{{cite journal |last1=Frisch |first1=Sm |last2=Francis |first2=H |title=Disruption of epithelial cell-matrix interactions induces apoptosis |journal=The Journal of Cell Biology |date=15 February 1994 |volume=124 |issue=4 |pages=619–626 |doi=10.1083/jcb.124.4.619 |pmid=8106557 |pmc=2119917 }}{{cite journal |last1=Zhang |first1=Z |last2=Vuori |first2=K |last3=Reed |first3=J C |last4=Ruoslahti |first4=E |title=The alpha 5 beta 1 integrin supports survival of cells on fibronectin and up-regulates Bcl-2 expression. |journal=Proceedings of the National Academy of Sciences |date=20 June 1995 |volume=92 |issue=13 |pages=6161–6165 |doi=10.1073/pnas.92.13.6161 |pmid=7541142 |pmc=41662 |doi-access=free |bibcode=1995PNAS...92.6161Z }} These findings essentially explained why normal cells stay in their appropriate place, whereas cancer cells spread and metastasize. Reduced integrin function in malignant cells enables them to leave their original tissue, and increased expression of anti-apoptotic proteins prevents anoikis, enabling cancer invasion and metastasis. The clinic has obtained several drugs for the treatment of cancer and other diseases based on the fundamental RGD/integrin and apoptosis studies at the institute.{{citation needed|date=October 2024}}

More recently, the institute has expanded its research to several additional areas, including neuroscience, cardiovascular diseases, and rare diseases of sugar and phosphate metabolism. The discoveries of proteins linked to disease development and identification of chemical compounds (or antibodies) that bind to those proteins and inhibit or enhance their function have become a common trend. Such compounds become candidate drugs for the treatment of the disease. Several compounds developed either at the Institute or by the biopharmaceutical companies are now in clinical trials.{{synthesis inline|date=September 2023}}{{ClinicalTrialsGov|NCT03517176|CEND-1 in Combination With Nabpaclitaxel and Gemcitabine in Metastatic Pancreatic Cancer}}{{Cite web |title=Clinical Evidence Supporting Therapeutic Potential of Activating the Immune Checkpoint Receptor BTLA in SLE |url=https://acrabstracts.org/abstract/clinical-evidence-supporting-therapeutic-potential-of-activating-the-immune-checkpoint-receptor-btla-in-sle/ |access-date=2025-05-02 |website=ACR Meeting Abstracts |language=en-US}}{{cite journal |last1=Maruyama |first1=Sonomi |last2=Visser |first2=Hester |last3=Ito |first3=Takashi |last4=Limsakun |first4=Tharin |last5=Zahir |first5=Hamim |last6=Ford |first6=Daniel |last7=Tao |first7=Ben |last8=Zamora |first8=Cynthia A. |last9=Stark |first9=Jeffrey G. |last10=Chou |first10=Hubert S. |title=Phase I studies of the safety, tolerability, pharmacokinetics, and pharmacodynamics of DS-1211, a tissue-nonspecific alkaline phosphatase inhibitor |journal=Clinical and Translational Science |date=April 2022 |volume=15 |issue=4 |pages=967–980 |doi=10.1111/cts.13214 |pmid=35021269 |pmc=9010257 }} The institute's pioneering studies demonstrated that simple sugars, including D-mannose, L-fucose, and D-galactose, are capable of effectively treating a set of rare genetic disorders. Some are currently in clinical trials.{{ClinicalTrialsGov|NCT05462587|A Study to Evaluate Efficacy and Safety of AVTX-803 in Patients With Leukocyte Adhesion Deficiency Type II}}{{ClinicalTrialsGov|NCT05402332|Evaluate Optimal Dosing and Long-term Safety of D-galactose in PGM1-CDG (AVTX-801)}}

{{unreferenced section|date=October 2024}}

File:CPCCG screening robot.jpg

Sanford Burnham Prebys has working relationships with the University of California, San Diego, The Scripps Research Institute, the Salk Institute for Biological Studies, and the Mayo Clinic.{{Citation needed|date=July 2025}}

Sanford Burnham Prebys also collaborates with pharmaceutical industry to move research breakthroughs from the lab out to wide adoption in clinical trials.{{Citation needed|date=July 2025}}

{{Reflist}}

• [http://www.sbpdiscovery.org/ Official website]
• https://sbpdiscovery.org/research/

{{authority control}}

Category:Medical research institutes in California

Category:Cancer organizations based in the United States

Category:Stem cell research

Category:La Jolla, San Diego

Category:Independent research institutes

Category:501(c)(3) organizations